GHRP-6 Dosage: Protocol, Hunger Management & Stack Guide

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the first synthetic growth hormone secretagogues studied in humans, with a research history extending back to the early 1980s. It remains one of the most widely referenced GHRPs in both academic literature and clinical practice. GHRP-6 activates the ghrelin receptor to stimulate pulsatile GH release from the pituitary gland, but it is unique among GHRPs for the pronounced hunger and appetite stimulation that accompanies its use — a direct consequence of ghrelin receptor activation in the hypothalamus. Understanding GHRP-6's dosing parameters, the hunger side effect and strategies for managing it, and how stacking with GHRH analogues enhances its effects is central to interpreting the research context surrounding this peptide.

Mechanism and Historical Research Context

GHRP-6 was among the first synthetic peptides demonstrated to stimulate GH release through a mechanism distinct from endogenous GHRH. While GHRH acts at the GHRH receptor on pituitary somatotrophs to promote GH synthesis and secretion, GHRP-6 and related peptides were found to act at a separate receptor — later identified as the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor — using a different intracellular signaling pathway. This distinction was pharmacologically significant because it explained how GHRPs and GHRHs could produce synergistic GH release when co-administered. The discovery that endogenous ghrelin — the "hunger hormone" — is the natural ligand for GHSR-1a explained why GHRP-6 stimulates appetite. GHRP-6 mimics ghrelin's receptor binding, and ghrelin's hypothalamic actions include potent stimulation of appetite and food-seeking behavior. GHRP-6's ghrelin-mimetic profile means it simultaneously stimulates GH release from the pituitary and activates appetite-promoting pathways in the hypothalamus — both effects that are mediated through GHSR-1a. The GH released in response to GHRP-6 administration stimulates liver production of IGF-1, which mediates many of the anabolic and recovery-associated effects attributed to GHRP-based protocols. The extent of GH release depends on individual pituitary responsiveness, the degree of somatostatin inhibition active at the time of injection (which is why fasted administration is standard), and whether a complementary GHRH signal is present.

Research Dose Ranges: 100–300 mcg Per Injection

GHRP-6 research protocols consistently describe doses in the range of 100–300 mcg per injection. This range encompasses the doses used in published human GH stimulation studies and those applied in clinical practice for GH axis assessment and therapeutic research. At 100 mcg, GHRP-6 produces a measurable and significant GH pulse in research subjects, demonstrating that even the lower portion of the dose range is biologically active. Studies in healthy adults have shown dose-dependent increases in GH release across the 100–300 mcg range, with peak GH responses typically occurring within 15–30 minutes of subcutaneous injection. The GH pulse magnitude from GHRP-6 alone, while significant, is generally lower than that produced by Hexarelin at equivalent doses — reflecting Hexarelin's greater potency at GHSR-1a. However, the difference in clinical relevance of this potency gap for real-world research outcomes is less clear, especially when GHRP-6 is stacked with a GHRH analogue to amplify the GH response. Doses above 300 mcg are sometimes discussed but are not standard in published research protocols. At higher doses, the dose-response curve for GH release tends to flatten due to partial receptor saturation, while the hunger side effect continues to increase — an unfavorable trade-off that discourages dose escalation beyond the established research range. Weight-adjusted dosing of approximately 1–2 mcg/kg body weight is used in some research contexts and produces dose ranges broadly consistent with the absolute 100–300 mcg figures for typical adult body weights.

• Standard research dose: 100–300 mcg per injection
• Dose-dependent GH response within this range
• GHRP-6 is less potent per mcg than Hexarelin but produces meaningful GH pulses
• Doses >300 mcg: diminishing GH returns, increasing hunger side effect

Fasted Administration: Why Timing Matters

Administering GHRP-6 in a fasted state is a consistent and important feature of research protocols, not a peripheral recommendation. The basis for this requirement is the inhibitory effect of elevated blood glucose and insulin on pituitary GH secretion — a phenomenon known as glucose-mediated suppression of GH release. Following a meal, rising blood glucose triggers insulin secretion and simultaneously increases hypothalamic somatostatin tone — the inhibitory neuropeptide that dampens pituitary GH secretion. When somatostatin levels are elevated, the pituitary's responsiveness to GH secretagogues including GHRP-6 is substantially reduced, meaning that the same dose of GHRP-6 administered in the postprandial state produces a markedly smaller GH pulse compared to the fasted state. Research has demonstrated that elevated glucose and insulin levels can attenuate GHRP-stimulated GH release by 50% or more compared to fasted conditions, which has a direct practical implication: administering GHRP-6 within 1–2 hours of a significant meal substantially reduces its effectiveness. Standard protocol guidance recommends at least 90 minutes to 2 hours of fasting before each GHRP-6 injection. For the morning dose, this typically means injecting before breakfast or at least 2 hours after any food intake. For pre-workout timing, this requires planning the pre-workout injection before eating the pre-workout meal. For the pre-sleep dose, it means allowing at least 2 hours after the last meal before injecting. The post-injection window — the period after administration during which eating is discouraged — is also discussed in protocol contexts. Many practitioners recommend waiting 20–30 minutes after GHRP-6 injection before eating, allowing the GH pulse to peak before the postprandial insulin response begins to attenuate the GH signal. Small amounts of protein or fat (without carbohydrates) may have less impact on the GH response than carbohydrate-containing meals, though exact food interaction effects for GHRP-6 have not been rigorously quantified.

The Hunger Side Effect: Management Strategies

GHRP-6's most distinctive and practically significant side effect is a pronounced increase in appetite and hunger that begins within 20–30 minutes of injection and can persist for 1–2 hours. This effect reflects the peptide's direct activation of GHSR-1a in the hypothalamus, mimicking the orexigenic (appetite-promoting) actions of endogenous ghrelin. The magnitude of GHRP-6-induced hunger can be substantial — many individuals using GHRP-6 in research contexts describe intense food cravings that are disproportionate to their typical appetite levels. Unlike the transient GH pulse, the hunger response can linger and lead to significant unplanned caloric intake if not anticipated and managed. For research protocols focused on GH elevation and recovery where caloric intake management is important, the hunger side effect creates a practical tension: administering GHRP-6 in a properly fasted state is necessary for maximal GH response, but the resulting hunger makes maintaining the desired dietary pattern challenging. Several management strategies are discussed in clinical and practitioner contexts. Timing GHRP-6 injections closer to planned meals — such that the hunger peak coincides with a meal that was already planned rather than triggering additional unplanned eating — is one approach. For the pre-sleep injection, some practitioners suggest that hunger is less problematic at this time because the window before sleep naturally limits the opportunity for food intake. Substituting GHRP-2 for GHRP-6 in protocols where hunger management is important is sometimes recommended, as GHRP-2 produces a similar GH secretagogue effect with less pronounced appetite stimulation. Some practitioners consider GHRP-6's appetite-stimulating effect an intentional feature in research contexts involving muscle building or recovery from illness-associated anorexia, where increased caloric intake is a desired outcome rather than a side effect to be managed.

• Hunger onset: 20–30 minutes post-injection; can persist 1–2 hours
• Mechanism: hypothalamic GHSR-1a activation mimicking ghrelin orexigenic effects
• Management: time injections near planned meals; pre-sleep dose limits unplanned eating
• Alternative: GHRP-2 produces similar GH effects with less appetite stimulation

Stacking with CJC-1295: Synergistic GH Release

Co-administering GHRP-6 with a GHRH analogue such as CJC-1295 (without DAC / Modified GRF 1-29) or Sermorelin is a standard feature of GH-optimization research protocols and represents one of the most well-established stack combinations in peptide research practice. The pharmacological rationale is robust: GHRP-6 and GHRH analogues act through completely distinct receptor systems to promote GH release, and their co-administration exploits both pathways simultaneously to produce GH pulses several times larger than either agent produces alone. GHRH (and analogues) binds to the GHRH receptor, activating the cyclic AMP/PKA intracellular signaling pathway to promote GH gene transcription and direct secretory activity. GHRP-6 binds to GHSR-1a, activating phospholipase C and calcium-dependent pathways, while also reducing somatostatin's inhibitory tone. When these two mechanisms converge on the same pituitary somatotroph simultaneously, the combined signal produces a synergistic amplification of GH secretion. Published research on GHRP/GHRH combinations in humans has demonstrated this synergy quantitatively, with co-administration of GHRP-2 and GHRH producing GH peaks multiple times larger than the sum of the individual agent responses. Similar synergy is observed with GHRP-6 combinations. CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is the most commonly recommended GHRH analogue for co-administration with GHRP-6, owing to its pharmacokinetic profile: a half-life of approximately 30 minutes that produces a pulse of GH release lasting roughly as long as the GHRP-6 response, making the two well-matched in terms of their active windows. Typical CJC-1295 without DAC doses used in this combination are 100–200 mcg per injection, administered at the same time as GHRP-6. CJC-1295 with DAC — the longer-acting version — is sometimes used but its extended pharmacokinetics (half-life of approximately 6–8 days) means it provides a tonic rather than pulsatile GHRH background, which has different characteristics from the pulsatile profile produced by the shorter-acting version.

Reconstitution Protocol

GHRP-6 is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water before injection. Standard reconstitution involves drawing bacteriostatic water into a sterile syringe and injecting it slowly into the GHRP-6 vial, directing the stream down the inner wall of the vial rather than forcefully onto the powder. The vial should be gently swirled — not shaken — until the powder is completely dissolved, yielding a clear solution. For a 5 mg vial reconstituted with 2.5 mL of bacteriostatic water, the resulting concentration is 2 mg/mL (2000 mcg/mL), allowing 0.1 mL to deliver 200 mcg — a convenient concentration for the typical research dose range. For a 5 mg vial reconstituted with 5 mL, the concentration is 1 mg/mL, and 0.1 mL delivers 100 mcg. The choice of reconstitution volume should be guided by the target dose and the practical resolution of the insulin syringe being used. Reconstituted GHRP-6 should be stored refrigerated at 2–8°C. Published stability data for reconstituted research peptides generally supports a 2–4 week refrigerated stability window, though this varies by specific peptide formulation and storage conditions. Exposure to light can degrade some peptides, making opaque or amber-glass vials preferable for storage. Bacteriostatic water — not sterile water — is recommended for multi-use vials because the benzyl alcohol preservative inhibits bacterial growth during the multi-injection period of a GHRP-6 protocol. Lyophilized unreconstituted GHRP-6 is more stable and should be stored at 2–8°C for short-term use or at −20°C for long-term storage, away from moisture and light.

Cycling: Duration and Rest Periods

GHRP-6 protocols typically follow cycling patterns of 4–8 weeks of active use followed by 2–4 weeks off, with the specific parameters influenced by the research objective and the individual's response. The rationale for cycling GHRP-6 is similar to that for other GHRPs: continuous receptor stimulation leads to progressive GHSR-1a desensitization, elevated somatostatin tone, and reduction in the GH release produced per dose. While GHRP-6 produces less severe desensitization than the more potent Hexarelin, progressive attenuation of the GH response with continuous use is observed and represents a practical reason to incorporate structured rest periods. A commonly described protocol structure involves 6 weeks of GHRP-6 use (typically in combination with CJC-1295) followed by 2–3 weeks off before the next cycle. Some practitioners describe transitioning from GHRP-6 to a less desensitizing GHRP (such as Ipamorelin) during rest periods from GHRP-6, with the goal of maintaining some level of GH axis stimulation while allowing GHSR-1a recovery from GHRP-6 exposure. The appropriateness of this approach, and whether receptor cross-desensitization between different GHRPs is a concern, has not been studied in controlled human research. Post-cycle considerations for GHRP-6 are simpler than for anabolic steroids or exogenous GH, since GHRP-6 stimulates endogenous GH production rather than suppressing it. Nevertheless, allowing the GH axis to operate without peptide stimulation during off periods is considered prudent to maintain long-term pituitary responsiveness and avoid the chronic adaptations that could develop with uninterrupted GHRP stimulation.

References

1. GHRP-6 stimulates growth hormone release in man (1989) — PubMed
2. Synergistic effect of GHRP-6 and GRF on GH release in normal men (1990) — PubMed
3. Ghrelin and the GHS receptor in central appetite regulation (2003) — PubMed
4. Growth hormone secretagogues: history, mechanism of action, and clinical development (1998) — PubMed
5. Effect of food on GHRP-6-stimulated GH secretion (1993) — PubMed